Attention proud owners of 13q deletion-Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?

[Yalokin]

In a study, comparing the efficiency of MLPA with cytogenetic and FISH, it was shown that patients with del(13)(q14.3q14.3) > 70% had an unfavorable prognosis and it was stated that FISH studies were also necessary for CLL patients with del(13q) in MLPA.

I thought about these, reading posts of our members with favorable profiles from the FISH analyses, why do they start treatment so early? And some are indolent.

Here may be one of the answers:molecularcytogenetics.biome...

[Lilsa]

Thanks Yalokin, interesting paper. It seems the more we learn the more there is to try to take on board!Keep walking

Lilsa

[Ptown]

Hello Yalokin, I, too,would like to thank you for sharing this paper with us. My scientific reading skills are a bit rusty, so it was a challenge to read. However, I am glad I did. Sending best wishes to you for a happy, healthy day. Carolyn

[EugeneL2]

Thank you for sharing the article. The percentage of deletion associated with time to first treatment in del 13q CLL patients is not new. For example, this paper has a more detailed comparison (Figure 3):

pubmed.ncbi.nlm.nih.gov/268...

I consider myself lucky 🤞 to be free of treatment 6.63 years after diagnosis, with an average of 85% deletion (2015: 90%; 2018: 79% and 87%).

[bennevisplace]

Thanks. Though more like it owns me.

No, actually we've had our disagreements but we're getting on OK at the moment.

[skipro]

Hi

There are current studies looking into the benefits of early treatment now that we have non-chemo options like venetoclax or acalabrutinib

Many experts believe early treatment with thes new targeted agents will prolong life and improve outcomes even with some of the markets previously thought to be poor prognostic markers with the older chemotherapy